Pharmafile Logo
Pharmafocus logo
Advanced Search

Epsilogen announces significant expansion of management team with three new senior hires

April 26, 2023
Business Services

London, 26 April 2023 – Epsilogen Ltd, a global leader in the development of novel immunoglobulin E (IgE) antibodies to …

News
Press release

Real-world data analysis shows significant improvement in glycaemic management when using a blood glucose monitor connected to the mySugr® app in UK users with type 2 diabetes

April 26, 2023
Business Services

Burgess Hill, 26 April 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that real world data shows a …

News
Press release

FDA shares safety warning on amniotic fluid eyedrops

April 26, 2023
Medical Communications

The US Food and Drug Administration (FDA) has released a Public Safety Notification on eyedrops containing amniotic fluid currently being …

News
max-bender-w5bn80xghre-unsplash_1

FDA grants accelerated approval for QALSODY (tofersen) as ALS treatment

April 26, 2023
Medical Communications

Biogen has announced that the US Food and Drug Administration (FDA) has approved QALSODY (tofersen) 100mg/15ml injection for the treatment …

News
national-cancer-institute-l8twzt4ccvq-unsplash_1

UCB and Huma Therapeutics collaborate on digital health solution to improve rare disease management

April 26, 2023
Medical Communications

Digital health company Huma Therapeutics and biopharmaceutical company UCB are partnering to offer a digital technology solution to aid patients …

News
jair-lazaro-0lrjo37r6nk-unsplash

Abbott announces two FDA clearances for life support system

April 26, 2023
Medical Communications

US-based medical devices and healthcare company Abbott has announced two new clearances from the US Food and Drug Administration (FDA) …

News

MiNA Therapeutics Enters Research Collaboration with BioMarin Pharmaceutical to Advance RNAa Platform Research in Rare Genetic Diseases

April 25, 2023
Business Services

London, United Kingdom, April 25, 2023 — MiNA Therapeutics, the pioneer of small activating RNA (RNAa) therapeutics, today announced a multi-target …

News
Press release

PureTech Founded Entity Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies

April 25, 2023
Business Services

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, noted today that its Founded …

News
Press release

Brain scanning technology to be used for clinical psychedelics trials in pioneering London start-up partnership

April 25, 2023
Business Services

London, UK: Commercial trials for psychedelics-assisted medical treatments will now have access to state-of-the-art brain scanning technology thanks to a …

News
Press release

Alchemab Therapeutics to present data profiling a novel antibody to Huntingtin Exon 1 at the CHDI Annual Huntington’s Disease Therapeutics Conference

April 25, 2023
Business Services

Cambridge, UK, April 25, 2023 – Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to …

News
Press release
national-cancer-institute-kmvohcb-w5g-unsplash_1

EMA validates marketing authorisation application for Jemperli with chemotherapy

April 25, 2023
Medical Communications

GSK has announced that the European Medicines Agency (EMA) has validated the company’s Type II Variation for a new indication …

News
testalize-me-0je8ynv4mis-unsplash

3B Pharmaceuticals and Novartis enter into licensing agreement for FAP-targeting technology

April 25, 2023
Research and Development

German biotechnology company 3B Pharmaceuticals (3BP) and Switzerland-based Novartis have announced that they have entered into a Global Exclusive Licensing …

News
hal-gatewood-_jbclosdsd4-unsplash

NICE publishes Final Appraisal Document for multiple myeloma drug

April 25, 2023
Medical Communications

The National Institute for Health and Care Excellence (NICE) has submitted a Final Appraisal Document (FAD) for the use of …

News
robina-weermeijer-so1l3jsdd3y-unsplash_2

AstraZeneca and Ionis share positive results from phase 3 trial for eplontersen

April 25, 2023
Medical Communications

AstraZeneca and Ionis have announced positive results from their phase 3 NEURO-TTRansform trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy …

News

National Institute for Health and Care Excellence recommends Darzalex® (daratumumab) with bortezomib and dexamethasone for routine use on the NHS as treatment for multiple myeloma

April 24, 2023
Business Services

High Wycombe, 24 April 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson are pleased to announce that the …

News
Press release

Sphere Fluidics begins work with partners on 3DSecret program to investigate mechanisms of metastasis in cancer

April 24, 2023
Business Services

Cambridge, UK, 24th April 2023: Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, …

News
Press release

Incyte Announces European Commission Approval of Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents

April 24, 2023
Business Services

WILMINGTON, Del. – April 20, 2023 – Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has granted a marketing …

News
Press release

Janssen Marks First Approval Worldwide for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) with EC Authorisation for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with BRCA1/2 Mutations

April 24, 2023
Business Services

BEERSE, Belgium, 21 April 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission …

News
Press release

NICE gives green light to ibrutinib plus venetoclax as first-line treatment option for chronic lymphocytic leukaemia

April 24, 2023
Business Services

High Wycombe, 21 April 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson is pleased to announce that the …

News
Press release
national-cancer-institute-9k4fglw6efq-unsplash

NICE recommends treatment combination for advanced leukaemia

April 24, 2023
Medical Communications

The National Institute for Health and Care Excellence (NICE) has recommended Janssen’s imbruvica (ibrutinib) alongside venetoclax as a treatment option …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026